L
Luis M. Ruilope
Researcher at European University of Madrid
Publications - 891
Citations - 109166
Luis M. Ruilope is an academic researcher from European University of Madrid. The author has contributed to research in topics: Blood pressure & Renal function. The author has an hindex of 94, co-authored 841 publications receiving 97778 citations. Previous affiliations of Luis M. Ruilope include Lund University & Mayo Clinic.
Papers
More filters
Journal ArticleDOI
Chronic kidney disease in Spain: Prevalence and impact of accumulation of cardiovascular risk factors
Manuel Gorostidi,Mercedes Sánchez-Martínez,Luis M. Ruilope,Auxiliadora Graciani,Juan J. de la Cruz,Rafael Santamaria,María Dolores del Pino y Pino,Pilar Guallar-Castillón,Fernando de Alvaro,Fernando Rodríguez-Artalejo,José R. Banegas +10 more
TL;DR: Prevalence of CKD increased considerably with the accumulation of CVRF, suggesting that CKD could be considered as a cardiovascular condition.
Journal ArticleDOI
Acute worsening of renal function during episodes of macroscopic hematuria in IgA nephropathy
Manuel Praga,Victor Gutierrez-Millet,José J. Navas,Luis M. Ruilope,José M. Morales,Jose M. Alcazar,Bello I,Jose L. Rodicio +7 more
TL;DR: It is concluded that a worsening of renal function can be observed frequently during the EMH and Tubular damage and obstruction by red blood cell casts may play a significant role in the pathogenesis of this complication.
Journal ArticleDOI
The Framingham prediction rule is not valid in a European population of treated hypertensive patients.
Sylvie Bastuji-Garin,Anne Deverly,Dominique Moyse,Alain Castaigne,Giuseppe Mancia,Peter W. de Leeuw,Luis M. Ruilope,Talma Rosenthal,Gilles Chatellier +8 more
TL;DR: The Framingham models should not be used to predict absolute CHD risk in the European population as a whole, however, these models may be used within each country, provided that cut-off points defining high-risk patients have been determined within each countries.
Journal ArticleDOI
The past, present and future of renin-angiotensin aldosterone system inhibition
Robert J. Mentz,George L. Bakris,Bernard Waeber,John J.V. McMurray,Mihai Gheorghiade,Luis M. Ruilope,Aldo P. Maggioni,Karl Swedberg,Ileana L. Piña,Mona Fiuzat,Christopher M. O'Connor,Faiez Zannad,Bertram Pitt +12 more
TL;DR: The history of RAAS inhibition is presented including a summary of key heart failure, myocardial infarction, hypertension and atrial fibrillation trials, and recent developments are discussed including implementation and optimization of current drug therapies.
Journal ArticleDOI
Glucose metabolism in patients with essential hypertension.
TL;DR: Two thirds of the patients attending hypertension clinics with essential hypertension show an abnormal glucose metabolism, and 2 or more cardiovascular risk factors are not controlled in the majority of patients.